查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602657

AlphaGlucosidase抑制劑市場：按藥物類別、分銷管道、最終用戶分類 - 全球預測 2025-2030

Alpha Glucosidase Inhibitors Market by Drug class (Acarbose (Precose), Miglitol (Glyset), Voglibose), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年阿爾法葡萄Glucosidase抑制劑市值為61,676萬美元，預計2024年將達到7,0376萬美元，複合年成長率為14.50%，預計2030年將達到159,149萬美元。

α-葡萄Glucosidase抑制劑（AGI）是一種口服抗糖尿病藥物，可減緩腸道中碳水化合物的吸收，從而減緩 2 型糖尿病患者餐後血糖值的上升。全球糖尿病盛行率的上升凸顯了對 AGI 的需求，這刺激了對補充生活方式介入和其他糖尿病治療的有效管理策略的需求。 AGI 主要用於治療第 2 型糖尿病，但正在進行的研究也在調查其在其他代謝疾病中的潛在用途。最終用途範圍主要包括醫院、診所、零售藥房以及為全球患者提供便利的線上藥局。這個市場主要是由糖尿病患者數量的增加、藥物配方的進步以及糖尿病管理意識的提高所推動的。新興市場存在機遇，醫療基礎設施改善，抗糖尿病藥物的取得也有所改善。然而，成長受到胃腸道疾病等副作用以及提供更全面血糖控制的新藥物類別的出現的限制。低收入地區也面臨價格敏感性和藥品核准嚴格監管要求的挑戰。創新包括最佳化 AGI 的藥物動力學以最大限度地減少副作用和提高患者的依從性，以及開發利用 AGI 和其他抗糖尿病藥物的互補作用的聯合治療可以成為焦點。此外，透過探索整合 AGI 的營養和生活方式干涉措施，可能會出現市場擴張的新途徑。市場的本質是動態的，競爭格局的特徵是大量的研發活動，因為公司努力透過產品差異化和有效性來獲得優勢。為了抓住新的商機，企業應該透過研發、監管合規以及與研究機構和醫療保健提供者的策略聯盟來投資擴大通用人工智慧的應用範圍。

主要市場統計
基準年[2023] 61676萬美元
預測年份 [2024] 70376萬美元
預測年份 [2030] 15.9149億美元
複合年成長率（%） 14.50%

市場動態：揭示快速發展的阿爾法Glucosidase抑制劑市場的關鍵市場洞察

供需的動態交互作用正在改變α-Glucosidase抑制劑市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 2 型糖尿病的流行和改進治療的需要
    • 鼓勵糖尿病管理的政府措施和措施
    • α-Glucosidase酶抑制劑聯合治療日益受到關注
  • 市場限制因素
    • 原料藥核准和給藥方案的困難
  • 市場機會
    • 持續研發活動以創造新的α-Glucosidase抑制劑
    • 提高 α-Glucosidase抑制劑療效的個人化醫療方法
  • 市場問題
    • 對消化器官系統道副作用和藥物交互作用的擔憂

波特的五力：駕馭阿爾法葡萄Glucosidase抑制劑市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解α葡萄Glucosidase抑制劑市場的外部影響

外部宏觀環境因素在塑造α-Glucosidase抑制劑市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解α-Glucosidase抑制劑市場的競爭格局

對阿爾法葡萄Glucosidase抑制劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：α 葡萄Glucosidase抑制劑市場供應商的績效評估

FPNV定位矩陣是評估α-Glucosidase抑制劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製阿爾法葡萄Glucosidase抑制劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對阿爾法Glucosidase抑制劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭格局中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 2 型糖尿病的盛行率和改善護理的需要
      • 政府促進糖尿病管理的措施和措施
      • 與α-Glucosidase抑制劑的聯合治療越來越受到關注
    • 抑制因素
      • API核准和給藥方案的困難
    • 機會
      • 持續研發活動以發現新的α-Glucosidase抑制劑
      • 提高 α-Glucosidase抑制劑療效的個人化醫療方法
    • 任務
      • 對胃腸道副作用和藥物交互作用的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 α 葡萄Glucosidase抑制劑市場：依藥物類別

  • 介紹
  • Acarbose（預防）
  • 米格列醇（Griset）
  • 伏格列波糖

第7章α葡萄Glucosidase抑制劑市場：按分銷管道

  • 介紹
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第 8 章 α 葡萄Glucosidase抑制劑市場：依最終用戶分類

  • 介紹
  • 居家醫療
  • 醫院/診所
  • 糖尿病專科中心

第9章北美和南美α葡萄Glucosidase抑制劑市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區α-Glucosidase抑制劑市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章α-歐洲、中東和非洲的Glucosidase抑制劑市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alkem Laboratories Ltd.
  • Avecia Healthcare
  • Bal Pharma Ltd.
  • Bayer AG
  • Biocon
  • BioVision Inc. by Abcam US Group Holdings Inc.
  • Cipla Ltd.
  • Elder Pharmaceuticals Ltd.
  • Empros Pharma AB
  • Glenmark Pharmaceuticals Ltd.
  • Lunan Pharmaceuticals Group
  • Manus Aktteva Biopharma LLP
  • Merck KGaA
  • Micro Labs Ltd.
  • Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
  • Novo Nordisk A/S
  • Samex Overseas
  • Sanofi SA
  • Shenzhen Haorui Pharmatech Co., Ltd.
  • Straight Healthcare
  • Strides Arcolab Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Wockhardt Ltd.
Product Code: MRR-456C7E866918

The Alpha Glucosidase Inhibitors Market was valued at USD 616.76 million in 2023, expected to reach USD 703.76 million in 2024, and is projected to grow at a CAGR of 14.50%, to USD 1,591.49 million by 2030.

Alpha Glucosidase Inhibitors (AGIs) are a class of oral antidiabetic medications that delay the absorption of carbohydrates in the intestine, thereby mitigating postprandial blood glucose spikes in Type 2 diabetes patients. Their necessity is underscored by the global rise in diabetes prevalence, fueling demand for effective management strategies that complement lifestyle interventions and other diabetic therapies. AGIs find applications primarily in managing Type 2 diabetes, but ongoing research is examining their potential use in other metabolic disorders. The end-use scope predominantly includes hospitals, clinics, and retail pharmacies, as well as online drug stores that facilitate easier access to patients globally. The market is primarily driven by the increasing number of diabetes patients, advances in drug formulations, and rising awareness about diabetes management. Opportunities arise in emerging markets with growing healthcare infrastructure and increasing accessibility to antidiabetic drugs. However, growth is limited by side effects such as gastrointestinal issues and the advent of newer drug classes that offer more comprehensive glycemic control. Price sensitivity in low-income regions and stringent regulatory requirements for drug approval also pose challenges. Innovations could focus on optimizing the pharmacokinetics of AGIs to minimize side effects and enhance patient adherence, as well as developing combination therapies that leverage the complementary benefits of AGIs with other antidiabetic drugs. Exploring nutritional and lifestyle interventions integrated with AGIs could also reveal new avenues for market expansion. The nature of the market is dynamic, with a competitive landscape characterized by significant research and development activities as companies strive to gain an edge through product differentiation and efficacy. To grasp emerging opportunities, businesses should invest in R&D, regulatory compliance, and broadening the scope of AGIs applications through strategic partnerships with research institutions and healthcare providers.

KEY MARKET STATISTICS
Base Year [2023] USD 616.76 million
Estimated Year [2024] USD 703.76 million
Forecast Year [2030] USD 1,591.49 million
CAGR (%) 14.50%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alpha Glucosidase Inhibitors Market

The Alpha Glucosidase Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of type 2 diabetes and need for improved care
    • Government initiatives and policies encouraging diabetes management
    • Increasing focus on combination therapies with alpha-glucosidase inhibitors
  • Market Restraints
    • Difficulties of API approval and dosing regimen
  • Market Opportunities
    • Ongoing R&D activities for new alpha-glucosidase inhibitor discovery
    • Personalized medicine approaches for improved alpha-glucosidase inhibitor efficacy
  • Market Challenges
    • Concerns associated with gastrointestinal side effects and drug interactions

Porter's Five Forces: A Strategic Tool for Navigating the Alpha Glucosidase Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alpha Glucosidase Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alpha Glucosidase Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alpha Glucosidase Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alpha Glucosidase Inhibitors Market

A detailed market share analysis in the Alpha Glucosidase Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alpha Glucosidase Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alpha Glucosidase Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alpha Glucosidase Inhibitors Market

A strategic analysis of the Alpha Glucosidase Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alpha Glucosidase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Avecia Healthcare, Bal Pharma Ltd., Bayer AG, Biocon, BioVision Inc. by Abcam US Group Holdings Inc., Cipla Ltd., Elder Pharmaceuticals Ltd., Empros Pharma AB, Glenmark Pharmaceuticals Ltd., Lunan Pharmaceuticals Group, Manus Aktteva Biopharma LLP, Merck KGaA, Micro Labs Ltd., Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd., Novo Nordisk A/S, Samex Overseas, Sanofi S.A., Shenzhen Haorui Pharmatech Co., Ltd., Straight Healthcare, Strides Arcolab Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Torrent Pharmaceuticals Ltd., and Wockhardt Ltd..

Market Segmentation & Coverage

This research report categorizes the Alpha Glucosidase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug class, market is studied across Acarbose (Precose), Miglitol (Glyset), and Voglibose.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End-Users, market is studied across Home Healthcare, Hospitals & Clinics, and Specialty Diabetes Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of type 2 diabetes and need for improved care
      • 5.1.1.2. Government initiatives and policies encouraging diabetes management
      • 5.1.1.3. Increasing focus on combination therapies with alpha-glucosidase inhibitors
    • 5.1.2. Restraints
      • 5.1.2.1. Difficulties of API approval and dosing regimen
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for new alpha-glucosidase inhibitor discovery
      • 5.1.3.2. Personalized medicine approaches for improved alpha-glucosidase inhibitor efficacy
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with gastrointestinal side effects and drug interactions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alpha Glucosidase Inhibitors Market, by Drug class

  • 6.1. Introduction
  • 6.2. Acarbose (Precose)
  • 6.3. Miglitol (Glyset)
  • 6.4. Voglibose

7. Alpha Glucosidase Inhibitors Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Alpha Glucosidase Inhibitors Market, by End-Users

  • 8.1. Introduction
  • 8.2. Home Healthcare
  • 8.3. Hospitals & Clinics
  • 8.4. Specialty Diabetes Centers

9. Americas Alpha Glucosidase Inhibitors Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alpha Glucosidase Inhibitors Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alpha Glucosidase Inhibitors Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alkem Laboratories Ltd.
  • 2. Avecia Healthcare
  • 3. Bal Pharma Ltd.
  • 4. Bayer AG
  • 5. Biocon
  • 6. BioVision Inc. by Abcam US Group Holdings Inc.
  • 7. Cipla Ltd.
  • 8. Elder Pharmaceuticals Ltd.
  • 9. Empros Pharma AB
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. Lunan Pharmaceuticals Group
  • 12. Manus Aktteva Biopharma LLP
  • 13. Merck KGaA
  • 14. Micro Labs Ltd.
  • 15. Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
  • 16. Novo Nordisk A/S
  • 17. Samex Overseas
  • 18. Sanofi S.A.
  • 19. Shenzhen Haorui Pharmatech Co., Ltd.
  • 20. Straight Healthcare
  • 21. Strides Arcolab Limited
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Takeda Pharmaceutical Co. Ltd.
  • 24. Torrent Pharmaceuticals Ltd.
  • 25. Wockhardt Ltd.

LIST OF FIGURES

  • FIGURE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALPHA GLUCOSIDASE INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ACARBOSE (PRECOSE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MIGLITOL (GLYSET), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY VOGLIBOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SPECIALTY DIABETES CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023